News articles about Vitae Pharmaceuticals (NASDAQ:VTAE) have been trending positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vitae Pharmaceuticals earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.5759388772491 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Vitae Pharmaceuticals (NASDAQ VTAE) remained flat at $21.00 during trading on Friday. Vitae Pharmaceuticals has a 12-month low of $4.08 and a 12-month high of $21.03. The firm has a 50-day moving average price of $18.81 and a 200-day moving average price of $11.50.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/10/28/vitae-pharmaceuticals-vtae-earns-daily-coverage-optimism-score-of-0-31.html.
Vitae Pharmaceuticals Company Profile
Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.